Could wearable technology help with the early detection of deadly brain cancers?

Ontario-based researchers led by Terry Fox New Investigator Dr. Phedias Diamandis are researching the possibility of harnessing the power of brain wearables to fill an unmet need in cancer care: the early detection of brain tumours.

Survey used to self-report cancer symptoms can be used to predict which patients with head and neck cancers will land in hospital

Findings published in the Journal of Clinical Oncology provide the first evidence that tools currently used by patients to report symptoms could be analyzed to pre-emptively identify who is at a higher risk of visiting the hospital, allowing clinicians to create interventions that address these issues early on.

Team finds cancer cells hibernate like bears to evade harsh chemotherapy

Patients with pancreatic ductal adenocarcinoma respond differently to treatment depending on which metabolic pathway alteration they display, according to a new discovery by a team of TFRI-funded researchers.

Researchers explore areas surrounding tumors for signatures associated with prostate cancer progression

Ontario-based researchers led by Dr. Hansen Housheng He have used single-cell RNA-sequencing to analyze the tumour microenvironment, helping them identify multiple tumour and microenvironment signatures associated with prostate cancer progression.

New finding sets the stage for clinical trial to better manage cancers that metastasize to the brain

A new finding by TFRI-funded researchers in Montreal is paving the way for the development of a clinical trial that compares patients with minimally invasive brain metastases receiving radiotherapy against patients who merely undergo observation with the goal of learning whether these patients can forego receiving aggressive treatments that do not provide them with benefits.

Study identifies biomarkers that predict which pancreatic cancer patients with germline BRCA mutations will benefit from personalized therapies

Members of TFRI’s Enhanced Pancreatic Cancer Profiling (EPPCP) research program have discovered which pancreatic cancer patients with germline BRCA mutations will benefit from personalized therapies using platinum and PARP inhibitors.

Study reveals key genetic mutation that leads to the development of aggressive pancreatic brain tumour

A study by a Quebec-based team that includes several TFRI-funded researchers has found that many patients with a subtype of gliomas known as G34R/V high-grade gliomas (G34R/V HGGs) exhibit a high frequency of activating mutations in a gene called PDGFRA, suggesting that this mutation leads to the development of this aggressive form of pediatric brain cancer.

TFRI NEWS

TFRI launches 2022 New Investigator Award competition

Marathon of Hope Cancer Centres Network accelerates precision medicine plan with signing of Contribution Agreement with Health Canada

Key leadership hired for new Digital Health and Discovery Platform (DHDP)

New Chief Financial Officer for TFRI will help steward new precision medicine projects and longstanding peer-review programs

Terry Fox Foundation appoints new Executive Director

The DHDP and Mitacs team up to launch innovative interdisciplinary training program of up to $2M to produce skilled STEM workers for Canada’s economy

TFRI is either the principal or supporting funder of the research presented here. Funded investigators are invited to submit their publications to us for consideration in an upcoming issue.

Keys to TFRI’s success

Marathon of Hope Cancer Centres Network accelerates precision medicine plan with signing of Contribution Agreement with Health Canada

TFRI launches 2022 New Investigator Award competition

Key leadership hired for new Digital Health and Discovery Platform (DHDP)

New Chief Financial Officer for TFRI will help steward new precision medicine projects and longstanding peer-review programs

Terry Fox Foundation appoints new Executive Director

The DHDP and Mitacs team up to launch innovative interdisciplinary training program of up to $2M to produce skilled STEM workers for Canada’s economy

TFRI is either the principal or supporting funder of the research presented here. Funded investigators are invited to submit their publications to us for consideration in an upcoming issue.

Terry Fox Research Institute Newsletter

Spring 2021

RESEARCH HIGHLIGHTS

Could wearable technology help with the early detection of deadly brain cancers?

Ontario-based researchers led by Terry Fox New Investigator Dr. Phedias Diamandis are researching the possibility of harnessing the power of brain wearables to fill an unmet need in cancer care: the early detection of brain tumours.

Survey used to self-report cancer symptoms can be used to predict which patients with head and neck cancers will land in hospital

Findings published in the Journal of Clinical Oncology provide the first evidence that tools currently used by patients to report symptoms could be analyzed to pre-emptively identify who is at a higher risk of visiting the hospital, allowing clinicians to create interventions that address these issues early on.

Team finds cancer cells hibernate like bears to evade harsh chemotherapy

Patients with pancreatic ductal adenocarcinomas respond differently to treatment depending on which metabolic pathway alteration they display, according to a new discovery by a team of TFRI-funded researchers.

Researchers explore areas surrounding tumors for signatures associated with prostate cancer progression

Ontario-based researchers led by Dr. Hansen Housheng He have used single-cell RNA-sequencing to analyze the tumour microenvironment, helping them identify multiple tumour and microenvironment signatures associated with prostate cancer progression.

New finding sets the stage for clinical trial to better manage cancers that metastasize to the brain

A new finding by TFRI-funded researchers in Montreal is paving the way for the development of a clinical trial that compares patients with minimally invasive brain metastases receiving radiotherapy against patients who merely undergo observation with the goal of learning whether these patients can forego receiving aggressive treatments that do not provide them with benefits.

Study identifies biomarkers that predict which pancreatic cancer patients with germline BRCA mutations will benefit from personalized therapies

Members of TFRI’s Enhanced Pancreatic Cancer Profiling (EPPPCP) research program have discovered which pancreatic cancer patients with germline BRCA mutations will benefit from personalized therapies using platinum and PARP inhibitors.

Study reveals key genetic mutation that leads to the development of aggressive pancreatic brain tumour

A study by a Quebec-based team that includes several TFRI-funded researchers has found that many patients with a subtype of gliomas known as G34R/V high-grade gliomas (G34R/V HGGs) exhibit a high frequency of activating mutations in a gene called PDGFRA, suggesting that this mutation leads to the development of this aggressive form of pediatric brain cancer.